Brokerages Anticipate Jaguar Health Inc (NASDAQ:JAGX) to Post -$0.25 EPS

Wall Street brokerages expect Jaguar Health Inc (NASDAQ:JAGX) to post ($0.25) earnings per share for the current quarter, according to Zacks. Two analysts have issued estimates for Jaguar Health’s earnings. Jaguar Health reported earnings per share of ($42.66) in the same quarter last year, which suggests a positive year over year growth rate of 99.4%. The company is expected to announce its next earnings report on Monday, November 18th.

On average, analysts expect that Jaguar Health will report full year earnings of ($5.31) per share for the current financial year, with EPS estimates ranging from ($5.49) to ($5.12). For the next financial year, analysts expect that the company will post earnings of ($1.30) per share, with EPS estimates ranging from ($2.39) to ($0.70). Zacks’ earnings per share calculations are an average based on a survey of analysts that cover Jaguar Health.

Jaguar Health (NASDAQ:JAGX) last posted its quarterly earnings results on Wednesday, August 14th. The biotechnology company reported ($9.09) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($5.61) by ($3.48). Jaguar Health had a negative net margin of 727.27% and a negative return on equity of 698.61%. The company had revenue of $1.71 million for the quarter, compared to analyst estimates of $3.05 million.

Several brokerages have recently issued reports on JAGX. LADENBURG THALM/SH SH began coverage on shares of Jaguar Health in a research note on Thursday, September 12th. They set a “buy” rating and a $5.00 price objective for the company. ValuEngine raised shares of Jaguar Health from a “hold” rating to a “buy” rating in a research note on Wednesday, October 2nd. Finally, Zacks Investment Research raised shares of Jaguar Health from a “sell” rating to a “hold” rating in a research note on Tuesday, October 22nd.

An institutional investor recently bought a new position in Jaguar Health stock. Wedbush Securities Inc. purchased a new position in shares of Jaguar Health Inc (NASDAQ:JAGX) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 25,100 shares of the biotechnology company’s stock, valued at approximately $33,000. Wedbush Securities Inc. owned 0.05% of Jaguar Health at the end of the most recent quarter. 0.11% of the stock is currently owned by hedge funds and other institutional investors.

Shares of JAGX stock traded down $0.03 during midday trading on Wednesday, reaching $0.74. 286,200 shares of the company traded hands, compared to its average volume of 492,870. Jaguar Health has a 1-year low of $0.64 and a 1-year high of $37.10. The firm’s 50 day simple moving average is $0.91 and its two-hundred day simple moving average is $1.75. The firm has a market cap of $37.09 million, a PE ratio of 0.00 and a beta of 0.71. The company has a debt-to-equity ratio of 0.02, a current ratio of 0.35 and a quick ratio of 0.24.

Jaguar Health Company Profile

Jaguar Health, Inc, a commercial stage natural-products pharmaceuticals company, focuses on developing gastrointestinal products for human prescription use and animals worldwide. The company, through its wholly-owned subsidiary, Napo Pharmaceuticals, Inc, focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas.

Recommended Story: Street Name

Get a free copy of the Zacks research report on Jaguar Health (JAGX)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Jaguar Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jaguar Health and related companies with's FREE daily email newsletter.


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit